BACKGROUND: The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for young patients with localized diffuse large B-cell lymphoma (DLBCL) was previously demonstrated. We report the results of a trial which evaluates the role of rituximab combined with ACVBP (R-ACVBP) in these patients. PATIENTS AND METHODS: Untreated patients younger than 66 years with stage I or II DLBCL and no adverse prognostic factors of the age-adjusted International Prognostic Index were randomly assigned to receive three cycles of ACVBP plus sequential consolidation with or without the addition of four infusions of rituximab. RESULTS:A total of 223 patients were randomly allocated to the study, 110 in the R-ACVBP group and 113 in the ACVBP group. After a median follow-up of 43 months, our 3-year estimate of event-free survival was 93% in the R-ACVBP group and 82% in the ACVBP group (P = 0.0487). Three-year estimate of progression-free survival was increased in the R-ACVBP group (95% versus 83%, P = 0.0205). Overall survival did not differ between the two groups with a 3-year estimates of 98% and 97%, respectively (P = 0.686). CONCLUSION: In young patients with low-risk localized DLBCL, rituximab combined with three cycles of ACVBP plus consolidation is significantly superior to ACVBP plus consolidation alone.
RCT Entities:
BACKGROUND: The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for young patients with localized diffuse large B-cell lymphoma (DLBCL) was previously demonstrated. We report the results of a trial which evaluates the role of rituximab combined with ACVBP (R-ACVBP) in these patients. PATIENTS AND METHODS: Untreated patients younger than 66 years with stage I or II DLBCL and no adverse prognostic factors of the age-adjusted International Prognostic Index were randomly assigned to receive three cycles of ACVBP plus sequential consolidation with or without the addition of four infusions of rituximab. RESULTS: A total of 223 patients were randomly allocated to the study, 110 in the R-ACVBP group and 113 in the ACVBP group. After a median follow-up of 43 months, our 3-year estimate of event-free survival was 93% in the R-ACVBP group and 82% in the ACVBP group (P = 0.0487). Three-year estimate of progression-free survival was increased in the R-ACVBP group (95% versus 83%, P = 0.0205). Overall survival did not differ between the two groups with a 3-year estimates of 98% and 97%, respectively (P = 0.686). CONCLUSION: In young patients with low-risk localized DLBCL, rituximab combined with three cycles of ACVBP plus consolidation is significantly superior to ACVBP plus consolidation alone.
Authors: Hervé Ghesquieres; Susan L Slager; Fabrice Jardin; Amelie S Veron; Yan W Asmann; Matthew J Maurer; Thierry Fest; Thomas M Habermann; Marie C Bene; Anne J Novak; Sylvain Mareschal; Corinne Haioun; Thierry Lamy; Stephen M Ansell; Herve Tilly; Thomas E Witzig; George J Weiner; Andrew L Feldman; Ahmet Dogan; Julie M Cunningham; Curtis L Olswold; Thierry Jo Molina; Brian K Link; Noel Milpied; David G Cox; Gilles A Salles; James R Cerhan Journal: J Clin Oncol Date: 2015-10-12 Impact factor: 44.544
Authors: Matthew J Maurer; Hervé Ghesquières; Brian K Link; Jean-Philippe Jais; Thomas M Habermann; Carrie A Thompson; Corinne Haioun; Cristine Allmer; Patrick B Johnston; Richard Delarue; Ivana N Micallef; Frederic Peyrade; David J Inwards; Nicolas Ketterer; Umar Farooq; Olivier Fitoussi; William R Macon; Thierry J Molina; Sergei Syrbu; Andrew L Feldman; Susan L Slager; George J Weiner; Stephen M Ansell; James R Cerhan; Gilles A Salles; Thomas E Witzig; Hervé Tilly; Grzegorz S Nowakowski Journal: J Clin Oncol Date: 2018-04-19 Impact factor: 44.544
Authors: Matthew J Maurer; Hervé Ghesquières; Jean-Philippe Jais; Thomas E Witzig; Corinne Haioun; Carrie A Thompson; Richard Delarue; Ivana N Micallef; Frédéric Peyrade; William R Macon; Thierry Jo Molina; Nicolas Ketterer; Sergei I Syrbu; Olivier Fitoussi; Paul J Kurtin; Cristine Allmer; Emmanuelle Nicolas-Virelizier; Susan L Slager; Thomas M Habermann; Brian K Link; Gilles Salles; Hervé Tilly; James R Cerhan Journal: J Clin Oncol Date: 2014-02-18 Impact factor: 44.544
Authors: C P Escalante; Y C Chang; K Liao; T Rouleau; J Halm; P Bossi; S Bhadriraju; N Brito-Dellan; S Sahai; S W Yusuf; A Zalpour; L S Elting Journal: Support Care Cancer Date: 2016-06-25 Impact factor: 3.603
Authors: Hervé Ghesquières; Beth R Larrabee; Corinne Haioun; Brian K Link; Aurélie Verney; Susan L Slager; Nicolas Ketterer; Stephen M Ansell; Richard Delarue; Matthew J Maurer; Olivier Fitoussi; Thomas M Habermann; Fréderic Peyrade; Ahmet Dogan; Thierry J Molina; Anne J Novak; Hervé Tilly; James R Cerhan; Gilles Salles Journal: Hematol Oncol Date: 2016-06-10 Impact factor: 5.271
Authors: Matthew J Maurer; Jean-Philippe Jais; Hervé Ghesquières; Thomas E Witzig; Fangxin Hong; Corinne Haioun; Carrie A Thompson; Catherine Thieblemont; Ivana N Micallef; Luis F Porrata; Vincent Ribrag; Gregorz S Nowakowski; Olivier Casasnovas; Serge Bologna; Franck Morschhauser; Vicki A Morrison; Bruce A Peterson; William R Macon; Christiane Copie-Bergman; Andrew L Feldman; Sergei I Syrbu; Paul J Kurtin; Randy D Gascoyne; Hailun Li; Cristine Allmer; Brad S Kahl; Stephen M Ansell; Susan L Slager; Brian K Link; Gilles Salles; Thomas M Habermann; Hervé Tilly; James R Cerhan Journal: Am J Hematol Date: 2015-11-26 Impact factor: 10.047
Authors: Daniel J Sargent; Qian Shi; Christopher R Flowers; Norbert Schmitz; Thomas M Habermann; Jocelyne Flament; Tommy Fu; Bertrand Coiffier Journal: Oncologist Date: 2017-08-10